Bronchogen (AEDL): Research Overview

What is Bronchogen?

Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function.

What is Bronchogen researched for?

• Supports bronchial tissue through gene expression regulation.
• Helps maintain respiratory epithelium health.
• Regulates protein synthesis in lung tissue.
• Addresses age-related changes in bronchial tissue.
• Modulates gene expression in respiratory cells.

How does Bronchogen work?

Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.

Pharmacokinetics

• Bronchogen's tetrapeptide structure allows it to penetrate cell nuclei directly and modulate gene expression epigenetically. Despite its short circulating half-life, it triggers lasting changes in DNA regulation and protein synthesis in bronchial tissue. These epigenetic changes persist long after the peptide itself clears circulation.

References

1. Khavinson Peptide Bioregulators

   Advances in Gerontology · 2020

   Comprehensive review of bioregulator peptides including respiratory bioregulators.

   Review or meta-analysis

2. Short Peptides and Bronchial Function

   Bulletin of Experimental Biology and Medicine · 2018

   Tetrapeptides derived from bronchial tissue regulate protein synthesis in respiratory cells.

3. Bioregulator Peptides and

   Respiratory Health Cell Technologies in Biology and Medicine · 2016

   Short peptides support bronchopulmonary system through epigenetic mechanisms.